

February 06, 2026

To
 The Manager
 Listing Department
 National Stock Exchange of India Limited
 Exchange Plaza, 5th Floor,
 Plot No. C-1, 'G' Block, Bandra - Kurla Complex,
 Bandra (East) Mumbai – 400 051.

(Company Symbol: RPGLIFE)

Dear Sir/Madam,

Sub: Clarification w.r.t. Financial Results submitted for the quarter and nine months ended on December 31, 2025.

With reference to your email dated February 03, 2026 related to the Financial Results submitted by the Company to the Exchange for the quarter ended December 31, 2025, we submit our reply as under:

1. Machine Readable Form / Legible copy of Financial Results not submitted-

The company has submitted the Financial Results in machine readable format which are legible as confirmed by the NSE official over telephonic call. The signed Financial Results are enclosed for your reference.

2. Financial Results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard - In Consolidated and Standalone Financial Results same figures are mentioned-

The Company has submitted the Financial Results along with Limited Review Report(s) issued by the Statutory Auditors of the Company as per format prescribed under Schedule III of the Companies Act, 2013 and as per Indian Accounting Standard. You may refer note no 4 of Consolidated Financial Results which states that-

"The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Parent, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was subsequently incorporated on December 24, 2025. The proposed transfer is intended to streamline the business structure and improve operational focus. The Company expects the transaction to be concluded by February 2026 or such other date as may be mutually agreed between the parties, subject to receipt of the requisite approvals and completion of customary conditions precedent. **The subsidiary has commenced business subsequent to the quarter end on January 6, 2026 and also submitted a declaration of commencement of business to the Ministry of Corporate Affairs on such date. Accordingly, the amounts disclosed in the standalone and consolidated financial results for the quarter ended December 31, 2025 are the same.** The transaction represents an internal reorganization of businesses under common control, as the Company will continue to hold 100% equity interest and retain control over the subsidiary subsequent to the transfer."



In view of the above, you will observe that the Company has duly complied with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Companies Act, 2013.

Kindly request you to take the same on record.

Yours sincerely,
For RPG Life Sciences Limited



Rajesh Shirambekar
Head – Legal & Company Secretary
Encl. as above

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2025 and year to date from April 1, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per Aruna Kumaraswamy
Partner
Membership No.: 219350
UDIN: 26219350C4UT4N2912



Place: Mumbai
Date: January 27, 2026

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	(Rs. in Lakhs)					
	Quarter ended		Nine months ended		Year ended	
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	18,003	18,168	17,271	53,063	51,034	65,343
2 Other Income	341	454	331	1,318	762	1,268
3 Total Income (1+2)	18,344	18,622	17,602	54,381	51,796	66,611
4 Expenses						
(a) Cost of Materials Consumed	3,479	3,272	3,019	9,955	8,337	11,026
(b) Purchases of Stock-in-Trade	4,363	3,878	2,270	11,547	7,392	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1,352)	(492)	322	(2,352)	800	861
(d) Employee Benefits Expense	3,532	3,616	2,871	10,518	9,454	12,614
(e) Finance Costs	25	12	12	50	44	62
(f) Depreciation and Amortisation Expense	538	522	546	1,574	1,606	2,143
(g) Other Expenses	4,005	3,991	3,873	11,969	11,635	15,363
Total Expenses	14,590	14,799	12,913	43,261	39,268	51,583
5 Profit before exceptional items and tax (3-4)	3,754	3,823	4,689	11,120	12,528	15,028
6 Exceptional items Income / (Expense) (Refer Note 3)	(842)	1,122	-	280	(2,730)	8,260
7 Profit before tax	2,912	4,945	4,689	11,400	9,798	23,288
8 Income tax expenses						
a. Current Tax	691	1,156	1,192	2,754	3,221	4,969
b. Deferred Tax	8	104	4	119	(12)	(5)
Total tax expenses	699	1,260	1,196	2,873	3,209	4,964
9 Profit for the period (7-8)	2,213	3,685	3,493	8,527	6,589	18,324
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(91)	(3)	2	(96)	7	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	23	1	(1)	24	(3)	37
Other Comprehensive Income Net of Tax	(68)	(2)	1	(72)	4	(110)
11 Total Comprehensive Income for the period (9+10)	2,145	3,683	3,494	8,455	6,593	18,214
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	13.38	22.28	21.12	51.56	39.84	110.80
(b) Diluted (in Rs.)	13.38	22.28	21.12	51.56	39.84	110.80

**SIGNED FOR IDENTIFICATION
BY**

**S R B C & CO LLP
MUMBAI**


Notes:

1. The above unaudited standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on January 27, 2026.
2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
3. Exceptional items:


Exceptional Income / (Expenses)	Quarter ended			Nine month ended		(Rs. in Lakhs) Year ended 31-03-2025
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
Transfer charges towards assignment of portion of leasehold rights made in earlier periods under Urban Land (Ceiling and Regulation) Act, 1976	-	-	-	-	-	(2,730)
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	-	-	-	-	-	9,893
Gain/(Loss) on account of fire incident - Refer note 3(a)	266	1,122	-	1,388	-	(1,633)
Impact of New Labour Codes - Refer note 3(b)	(1,108)	-	-	(1,108)	-	-
Total exceptional items - Income / (Expenses)	(842)	1,122	-	280	(2,730)	8,260

- 3(a) On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra resulting in an impact on part of the Building, Plant & Machinery, inventories and other assets of the said manufacturing block. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in this incident. The assets impacted due to the fire incident are adequately covered under an insurance policy. The Company has performed a comprehensive analysis of the estimated loss arising on account of the fire incident for majority of the assets impacted by the fire and accordingly submitted a provisional insurance claim for the estimated loss. Based on such final assessment and estimates of cost, the Company has recognised a cumulative loss of Rs. 2,295 lakhs till date (net of write back of loss of Rs 266 lakhs for the quarter ended December 31, 2025). The Insurance Company has acknowledged the claim and has so far released five tranches of interim payment aggregating Rs. 2,050 lakhs (Rs. 850 lakhs for the year ended March 31, 2025 and Rs. 1,200 lakhs for the quarter and six months ended September 30, 2025). The Company has netted off the payments received from the Insurance Company with loss assessed due to damage caused by fire and the same is reflected under exceptional items for the respective periods. The net loss stands at Rs. 245 lakhs as on December 31, 2025 and the Company is confident of recovering this loss from the insurance company in subsequent quarters. The final amount of the approved claim from the Insurance company will be determined based on finalisation of such claim, and additional net gain/loss, if any, would be accounted in subsequent quarters.
- 3(b) The Government of India notified the four Labour Codes ('New Labour Codes') effective November 21, 2025. The Ministry of Labour & Employment has also issued draft Central Rules and FAQS to help assess the financial impact of these changes. The Company has assessed the estimated impact arising on account of the changes in the New Labour Codes especially due to the change in wage definition based on its best judgement in consultation with external experts. Accordingly, the Company has recognised incremental estimated obligations aggregating Rs. 1,108 Lakhs based on actuarial valuation in accordance with Ind AS 19 - 'Employee Benefits' and consistent with guidance provided by the Institute of Chartered Accountants of India. The incremental impact has been disclosed as an exceptional item given the non-recurring nature of this expense arising on account of a regulatory change. The Company is in the process of reassessing and implementing policy changes to its existing employee benefit policies. The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect on the basis of such developments, if any, as required.
4. The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Company, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was subsequently incorporated on December 24, 2025. The proposed transfer is intended to streamline the business structure and improve operational focus. The Company expects the transaction to be concluded by February 2026 or such other date as may be mutually agreed between the parties, subject to receipt of the requisite approvals and completion of customary conditions precedent. The subsidiary has commenced business subsequent to the quarter end on January 6, 2026 and also submitted a declaration of commencement of business to the Ministry of Corporate Affairs on such date. The transaction represents an internal reorganization of businesses under common control, as the Company will continue to hold 100% equity interest and retain control over the subsidiary subsequent to the transfer.

For RPG Life Sciences Limited


 Ashok Nair
 Managing Director
 DIN: 07906710

Place: Mumbai
 Date: January 27, 2026



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of RPG Life Sciences Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the subsidiary Company 'RPG Active Pharma Limited'.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Aruna Kumaraswamy

Partner

Membership No.: 219350

UDIN: 26219350YTWHLX9932

Place: Mumbai

Date: January 27, 2026



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	(Rs. in Lakhs)					
	Quarter ended		Nine months ended		Year ended	
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	18,003	18,168	17,271	53,063	51,034	65,343
2 Other Income	341	454	331	1,318	762	1,268
3 Total Income (1+2)	18,344	18,622	17,602	54,381	51,796	66,611
4 Expenses						
(a) Cost of Materials Consumed	3,479	3,272	3,019	9,955	8,337	11,026
(b) Purchases of Stock-in-Trade	4,363	3,878	2,270	11,547	7,392	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1,352)	(492)	322	(2,352)	800	861
(d) Employee Benefits Expense	3,532	3,616	2,871	10,518	9,454	12,614
(e) Finance Costs	25	12	12	50	44	62
(f) Depreciation and Amortisation Expense	538	522	546	1,574	1,606	2,143
(g) Other Expenses	4,005	3,991	3,873	11,969	11,635	15,363
Total Expenses	14,590	14,799	12,913	43,261	39,268	51,583
5 Profit before exceptional items and tax (3-4)	3,754	3,823	4,689	11,120	12,528	15,028
6 Exceptional items Income / (Expense) (Refer Note 3)	(842)	1,122	-	280	(2,730)	8,260
7 Profit before tax	2,912	4,945	4,689	11,400	9,798	23,288
8 Income tax expenses						
a. Current Tax	691	1,156	1,192	2,754	3,221	4,969
b. Deferred Tax	8	104	4	119	(12)	(5)
Total tax expenses	699	1,260	1,196	2,873	3,209	4,964
9 Profit for the period (7-8)	2,213	3,685	3,493	8,527	6,589	18,324
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(91)	(3)	2	(96)	7	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	23	1	(1)	24	(3)	37
Other Comprehensive Income Net of Tax	(68)	(2)	1	(72)	4	(116)
11 Total Comprehensive Income for the period (9+10)	2,145	3,683	3,494	8,455	6,593	18,214
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	13.38	22.28	21.12	51.56	39.84	110.80
(b) Diluted (in Rs.)	13.38	22.28	21.12	51.56	39.84	110.80

**SIGNED FOR IDENTIFICATION
BY**

**S R B C & CO LLP
MUMBAI**


Notes:

1. The above unaudited consolidated financial results of RPG Life Sciences Limited ("the Company" or "the Parent") and its subsidiary ("the Group") for the quarter and nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on January 27, 2026.
2. The Group operates in only one reportable business segment i.e. Pharmaceuticals.
3. Exceptional items:

Exceptional Income / (Expenses)	Quarter ended			Nine month ended		Year ended
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Transfer charges towards assignment of portion of leasehold rights made in earlier periods under Urban Land (Ceiling and Regulation) Act, 1976	-	-	-	-	(2,730)	-
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	-	-	-	-	-	9,893
Gain/(Loss) on account of fire incident - Refer note 3(a)	266	1,122	-	1,388	-	(1,633)
Impact of New Labour Codes - Refer note 3(b)	(1,108)	-	-	(1,108)	-	-
Total exceptional items	(842)	1,122	-	280	(2,730)	8,260

- 3(a) On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Group located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra resulting in an impact on part of the Building, Plant & Machinery, inventories and other assets of the said manufacturing block. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in this incident. The assets impacted due to the fire incident are adequately covered under an insurance policy. The Group has performed a comprehensive analysis of the estimated loss arising on account of the fire incident for majority of the assets impacted by the fire and accordingly submitted a provisional insurance claim for the estimated loss. Based on such final assessment, the Group has recognised a cumulative loss of Rs. 2,295 lakhs till date (net of write back of loss of Rs 266 lakhs for the quarter ended December 31, 2025). The Insurance Company has acknowledged the claim and has so far released five tranches of interim payment aggregating Rs. 2,050 lakhs (Rs. 850 lakhs for the year ended March 31, 2025 and Rs. 1,200 lakhs for the quarter and six months ended September 30, 2025). The Group has netted off the payments received from the Insurance Company with loss assessed due to damage caused by fire and the same is reflected under exceptional items for the respective periods. The net loss stands at Rs. 245 lakhs as on December 31, 2025 and the Group is confident of recovering this loss from the insurance company in subsequent quarters. The final amount of the approved claim from the Insurance company will be determined based on finalisation of such claim, and additional net gain/loss, if any, would be accounted in subsequent quarters.
- 3(b) The Government of India notified the four Labour Codes ('New Labour Codes') effective November 21, 2025. The Ministry of Labour & Employment has also issued draft Central Rules and FAQS to help assess the financial impact of these changes. The Group has assessed the estimated impact arising on account of the changes in the New Labour Codes especially due to the change in wage definition based on its best judgement in consultation with external experts. Accordingly, the Group has recognised incremental estimated obligations aggregating Rs. 1,108 Lakhs based on actuarial valuation in accordance with Ind AS 19 - 'Employee Benefits' and consistent with guidance provided by the Institute of Chartered Accountants of India. The incremental impact has been disclosed as an exceptional item given the non-recurring nature of this expense arising on account of a regulatory change. The Group is in the process of reassessing and implementing policy changes to its existing employee benefit policies. The Group continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect on the basis of such developments, if any, as required.
4. The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Parent, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was subsequently incorporated on December 24, 2025. The proposed transfer is intended to streamline the business structure and improve operational focus. The Company expects the transaction to be concluded by February 2026 or such other date as may be mutually agreed between the parties, subject to receipt of the requisite approvals and completion of customary conditions precedent. The subsidiary has commenced business subsequent to the quarter end on January 6, 2026 and also submitted a declaration of commencement of business to the Ministry of Corporate Affairs on such date. Accordingly, the amounts disclosed in the standalone and consolidated financial results for the quarter ended December 31, 2025 are the same. The transaction represents an internal reorganization of businesses under common control, as the Company will continue to hold 100% equity interest and retain control over the subsidiary subsequent to the transfer.

For RPG Life Sciences Limited



Ashok Nair
 Managing Director
 DIN: 07906710

Place: Mumbai
 Date: January 27, 2026

